Personalis at Liquid Biopsy for Precision Oncology Summit US: 10th-11th February 2022

NeXT Personal: Next Generation MRD Testing for Solid Tumors

Dan Norton
February 10: 12:30-1:00 PM PST
Dan Norton, MBA
Associate Director, Product Management
Personalis, Inc.

The ability to monitor and predict molecular recurrence at the earliest timepoints during or after curative therapy in patients previously diagnosed with cancer may inform precision treatment regimens, or spare patients from costly side effects. Here we discuss NeXT Personal, an advanced next generation MRD platform optimized for sensitivity to detect cancer at the earliest timepoints.

Connect with us at Liquid Biopsy for Precision Oncology Summit US 2022